Physician profile
Michael Weilert
NPI 1629015466
$8,273.91
in general payments reported to CMS, 2019-2025
29 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 89% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,318 · 2020: $946 · 2021: $1,484 · 2022: $1,193 · 2023: $1,167 · 2024: $1,012 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,332.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,097.28 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $1,306.75 | 2019-2022 | |
| Lilly USA, LLC | $534.34 | 2019-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.21 | 2020-2024 | Jardiance |
| Novo Nordisk INC | $473.39 | 2019-2025 | Ozempic |
| Amarin Pharma, INC. | $391.70 | 2019-2022 | |
| Glaxosmithkline, LLC. | $302.10 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $282.10 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $155.59 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $146.47 | 2021 | |
| Merck Sharp & Dohme LLC | $129.85 | 2019-2023 | Belsomra |
| Abbvie INC. | $129.71 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2024 | |
| Galderma Laboratories, L.P. | $124.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $98.31 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $73.77 | 2020 | |
| Exact Sciences Corporation | $67.62 | 2024 | Cologuard Collection Kit |
| Nevro Corp. | $45.38 | 2021-2023 | Senza |
| Idorsia Pharmaceuticals US INC | $39.39 | 2023-2025 | Quviviq, Quviviq |
| Pfizer INC. | $38.02 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.64 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.33 | 2021-2023 | |
| Mylan Specialty L.P. | $23.30 | 2024 | Yupelri |
| Astellas Pharma US INC | $20.43 | 2021 | |
| Eisai INC. | $20.06 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.05 | 2019 | |
| Shield Therapeutics INC | $19.04 | 2023 | Accrufer |
| Seqirus USA INC | $16.43 | 2024 | Fluad, Flucelvax |
| Mannkind Corporation | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Weilert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.